Emerging safety issues in alemtuzumab-treated MS patients

Mult Scler. 2019 Aug;25(9):1206-1208. doi: 10.1177/1352458519851219.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Incidence
  • Multiple Sclerosis*
  • Multiple Sclerosis, Relapsing-Remitting*

Substances

  • Antibodies, Monoclonal, Humanized
  • Alemtuzumab